Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Pulse Biosciences (PLSE) stock in plain English

Free brief · no signupStart here
PLSEPublished Nov 17, 2026
Pulse Biosciences Inc
Healthcare · Medical Instruments & Supplies
Develops medical devices that use nanosecond electrical pulses to clear targeted cellular tissue. Sells consoles and disposable treatment tips to specialty medical clinics.
Assets:
Hayward headquartersHouses research, engineering laboratories, and operations in California.
nsPFA platformDelivers electrical pulses lasting billionths of a second to disrupt cells.
CellFX systemComprises a tunable console and single-use handpieces for targeted tissue treatment.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

69
OPS ScoreOperating finances
Latest quote
-3.10%$44.41
$3.27B
n/a (loss)
$1.49M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was PLSE. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Pulse Biosciences (PLSE) do?

Pulse Biosciences Inc (PLSE) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Develops medical devices that use nanosecond electrical pulses to clear targeted cellular tissue. Sells consoles and disposable treatment tips to specialty medical clinics. Uses nanosecond electrical pulses to clear diseased cells while sparing surrounding non-cellular tissue structures. It is worth $3.27B on the market and sold $1.49M over the last year.

Market cap
$3.27B
P/E ratio
None (reported a loss)
Annual sales
$1.49M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 17, 2026

Brands and businesses behind PLSE

  • CellFX: Delivers pulsed electric fields to clear soft tissue lesions, generating revenue from console placements and single-use procedural tips.

PLSE’s flags, in plain English

Each flag is a number from Pulse Biosciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 14.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 3% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 69.7% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -5603.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about PLSE

How big is Pulse Biosciences?

Pulse Biosciences’ market cap is $3.27B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.49M: what customers paid the company over the last year, before any costs.

What is PLSE’s P/E ratio?

PLSE has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with PLSE?

The business generates very little commercial revenue and runs at a substantial ongoing net loss while funding clinical trials. That is one risk on Pulse Biosciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Pulse Biosciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PLSE’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card